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Venoms and Toxins
Is there a problem with venomous snakes?
Venomous snakes are unlikely to be a problem if your 
home is in Europe. However, if you live in South America, 
Africa or South East Asia, then they are more likely to 
be a reality for you, your family or someone you know. 
In many developing countries, people work in the fields, 
plantations, forests or similar. Such habitats are also 
hunting grounds for venomous snakes, often seeking out 
Since Adam and Eve, humankind has been equally frightened and fascinated by snakes. The ancient 
Egyptians worshipped the cobra, which decorate sarcophagi and the famous mask of Tutankhamun. 
Even today, the snake is integral to the Staff of Asclepius, a symbol of medicine. To some extent, medicine 
has forgotten about the snake, however, bites from venomous snakes still pose a deadly impact on 
people in low-and middle-income countries. It is estimated that venomous snakes kill between 
81,000 and 137,000 people every year, and maim around 400,000, which represents a huge impact 
both on families and social economics. Around 125 years ago, Calmette began to produce antivenom 
serum for snakebite victims. Since then, production methods have not changed significantly; then 
and now, antivenom is made by immunizing animals. Isolated antibodies can neutralize some of the 
most lethal toxins, thereby saving many lives. However, there is still a need for animals such as horses 
or sheep, as well as a snake farm, in order to acquire enough venom for immunization procedures. 
Animal-derived antibodies pose a threat, because they are foreign components injected into the 
human body, which can give rise to adverse immunogenic reactions. In a worst-case scenario this 
can lead to anaphylactic shock and death. Synthetic antivenom, is an interesting avenue, which could 
reduce or entirely remove the need for immunized animals and snake farms. Synthetic antivenoms 
could be made to high purity and eliminate many current challenges, such as batch-to-batch 
variations, high costs, limited shelf life and the need for ‘cold-chain’ transportation.
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rodents. Alongside this, primitive housing, litter (which 
attracts vermin) and the continuous expansion of villages 
and cities, increases the risk of encountering snakes. In 
the ocean, venomous sea snakes present a threat to those 
in the water, and especially to fishermen who accidently 
get bitten whilst working (which might actually involve 
hunting these very snakes, since they are considered a 
delicacy in some parts of the world). In 2017, the World 
Health Organization (WHO) placed snakebite on its list 
of the world’s most neglected diseases. It is estimated that 
venomous snakes kill between 81,000 and 137,000 people 
every year, and maim around 400,000, leaving a huge 
impact on family life and their economic opportunities. 
Compared with other ‘traditional’ neglected tropical 
diseases, such as cholera (69,000 deaths per year), 
leishmaniasis (24,000) and Chaga’s disease (8000), snake 
envenomization is therefore the largest killer. 
 
Can’t we just give antibodies to all 
snakebite victims?
As noted earlier, the methods for producing antivenom 
have changed little during the past century. Then and 
now, antivenom is made by immunizing animals and 
isolating the antibodies that can neutralize some of the 
most lethal toxins, thereby saving many lives. Many of 
these antivenoms are very effective, but these are often 
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expensive, and far beyond the reach of a fieldworker 
from Africa. Other antivenoms do not work as well, 
either because they are inherently poor quality or 
because they were developed as treatment for venom of 
a different species of snake to the one that has bitten the 
victim. Some antivenoms can cost up to $2000–3000 per 
vial, and treatment often requires 5–6 vials. Even if the 
cost is lowered and we reach a treatment with antivenom 
around $200–300, this is not affordable by most people 
in developing countries.   
 Making antivenom is a complicated and lengthy 
procedure. First, you need to have a large number of 
venomous snakes of the species against which you want 
to raise an antivenom. You then have to milk the snakes, 
but this often gives only a low yield. Even a relatively large 
sea snake, for example, often produces no more than a 
150 µl. A large puff adder delivers more, around 600 µl. 
You then have to inject it into an animal, e.g., a horse, 
and wait; it often takes around a year before the horse has 
enough antibody to be bled for the antibody of interest. 
Thereafter several purification steps are necessary. Even 
then the desired neutralizing antibody is only a small 
part of the entire antivenom. Consequently, antivenoms 
can consist of many impurities, which can lead to adverse 
reactions. Furthermore, the more impurities, the more 
vials you need to neutralize the target venom, which also 
increases the risks of anaphylactic shock.
 If the pharmaceutical industry could make better 
quality antibodies or a synthetic version, then perhaps 
we would have cheaper, safer and more efficient 
antivenoms. However, one of the major problems right 
now is not the lack of new and better (e.g., synthetic) 
antivenom, but rather lack of access to the existing ones. 
In a study carried out in 2010, it was estimated that only 
2% of people bitten by venomous snakes in sub-Saharan 
Africa have access to quality antivenom treatment. 
 Some of the antivenoms used today are quite cost-
effective. Unfortunately, we just cannot get enough to 
Figure 1. The ouroboros 
of antivenom shortage, 
showing that even 
though we have good-
quality antivenom, it is 
outcompeted by the poor-
quality copies, which do 
not work properly or even 
cause illness. People then go 
back to traditional medicine, 
and seek other aids, leading 
the demands for the good 
(but expensive) antivenom 
to drop. This eventually 
leads to companies 
discontinuing production 
and the market dies, a 
vicious circle as Médecins 
Sans Frontières termed it.
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accommodate all the snakebite victims. This is due to the 
discontinuation of production; an example of this is Sanofi 
Pasteur’s discontinuation of Fav-Afrique® a polyvalent 
antivenom previously used to treat envenoming by some 
snake species of sub-Saharan Africa. Today, we face a 
situation termed the antivenom crisis (see Figure 1, ‘the 
ouroboros of antivenom shortage’ illustration).
Why doesn’t the pharmaceutical industry 
solve the antivenom crisis?
The vicious slithering road to antivenom shortage is a cause 
and effect scenario, leading ultimately to pharmaceutical 
companies avoiding the market altogether. This is not a 
cheap venture. As mentioned earlier, snake farms and 
horses in which to raise antibodies are a necessity. Costs 
include training staff to take care of the animals, milk 
the snakes on a regular basis, plus vet bills. Production, 
purification and shipping costs drive up the price. From 
a business point of view, low market demand, which 
in turn prohibits a good economy scale for antivenom 
manufacturers, is a major disincentive. Furthermore, the 
poor quality of some products, that either do direct harm 
or do not work, creates mistrust in the market and people 
turn to the local medicine man or healer instead. For many 
pharmaceutical companies, antivenom manufacture is 
simply not a worthwhile venture. The few quality products 
(such as CroFab®), therefore, demand high prices, which 
are further inflated by the insurance companies. At 
the extreme end of the scale, snakebite treatment at a 
US hospital, might cost $100,000! Fortunately, most 
treatments are much cheaper. However, even if a quality 
antivenom vial can be acquired for $300, or less (e.g., 
Echitab-Plus-ICP) that is still roughly 6 months of salary 
for a Swazi farmer! Newer brands of antivenom sell for 
$30 or less per vial, however, most often the quality is 
poor, it does not work or in worst cases it can kill you.
So how can we solve the antivenom crisis?
The WHO are working on a roadmap to tackle snakebites. 
Médecins Sans Frontières (MSF) is perhaps the most 
important player, as they give snakebite victims 
antivenom free of charge at their clinics around the 
world. In Africa many lives are saved every day because 
MSF can administer good-quality antivenom to snake- 
bite victims, in for example, Abdurafi in Ethiopia. 
MSF also collaborates with researchers and have many 
good initiatives to increase awareness and knowledge 
of snakebites. In their access campaign, MSF has 
described the steps necessary for achieving a successful 
long-term plan (www.msfaccess.org).
These include:
• A list of safe and effective antivenom products.
• These quality antivenoms should be available free of 
   charge or at a price all can afford.
• Hotspots for snakebites in each country need to be 
   mapped, to choose the correct antivenom.
• Quality antivenoms must be stockpiled, nationally 
   and regionally.
• R&D must be better financed in order to improve 
   existing antivenoms and facilitate the next generation 
   of antivenoms. 
The next generation of antivenoms
The next generation of antivenoms could be synthetic, made 
in the lab using DNA recombinant technology, peptide 
synthesis and/or chemistry. The three main research 
fields are currently: 1) antibody-based, 2) peptide- 
based and 3) small-molecule antivenoms. There are also 
other strategies and initiatives, such as nanoparticles 
and large synthetic macromolecules.
 The vast majority of work continues to involve various 
strategies for manufacturing antibody-based antivenoms. 
Major breakthroughs have made it possible to undertake 
antibody engineering, in order to make improved 
versions of existing antibodies. In 1985, George Smith 
developed an elegant method known as phage display, 
where a bacteriophage—a virus that infects bacteria—can 
be used to evolve and identify new proteins (antibodies) or 
peptides, which can be used as ligands for developing new 
synthetic antivenom. Gregory Winter used phage display 
for the directed evolution of antibodies, with the aim of 
producing new pharmaceuticals. The first one based on 
this method, Adalimumab, was approved in 2002 and is 
used for rheumatoid arthritis, psoriasis and inflammatory 
bowel diseases. Since then, phage display has produced 
antibodies that can neutralize toxins, counteract 
autoimmune diseases and cure metastatic cancer. In our 
research at UCPH, AntiVenom Venture (AVV) focus on 
identifying and developing new antivenoms based on 
peptides. We use phage display to attempt to find new 
peptides that can bind and neutralize snake toxins. We also 
seek naturally occurring peptides and proteins, where part 
of these can be used as scaffolds to neutralize snake toxins. 
I have designated this class of compounds SerpentidesTM. 
These are peptides or peptide-based compounds that can 
bind and/or inhibit snake toxins. They can be naturally 
occurring compounds, or part of a larger protein, where 
this interacting part is synthesized individually, or a 
peptide identified through, e.g., phage display. I find this 
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an interesting and different strategy, from the antibody-
based strategy. These Serpentides could be a new and 
interesting alternative to the antibody-based strategy 
that most are pursuing. There are many advantages 
with a synthetic peptide-based antivenom, such as ease 
of chemical modification, smaller molecular weight, 
higher shelf stability, larger formulation possibilities and 
knowledge base for designed PD and PK. However, there 
are also disadvantages, such as short half-life in blood and 
solubility issues, but these could potentially be improved 
via chemical modifications. Crystallization of the peptide 
complexed with the target is often possible, providing 
important knowledge about peptide–toxin interactions. 
 Additionally, peptides can penetrate cells and skin, 
thereby giving new possibilities for treatment delivery. 
Serpentides could be formulated as an inhalant, as 
skin cream (for topical application at the location of 
the bite) or subcutaneous, in combination with, e.g., 
traditional antivenom.
 As it stands, we currently remain a long way from 
clinical application of peptides as antivenom. However, 
this is exactly the kind of strategy needed to expand 
existing routes to antivenom production. A push for new 
treatments for snakebites could literally prove life-saving 
for some of the most vulnerable people on the planet. ■
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